Industry News
Pharmaceutical Industry News
Cardiovascular Benefits of Wegovy Extend Beyond Weight Loss, Study Shows
An analysis found that a shrinking waist size was responsible for only around a third of the cardiovascular benefits in people who took Wegovy.
We’re at a tipping point in…
We’re at a tipping point in Alzheimer's disease, with new treatments, multiple validated targets and advanced CNS delivery methods converging.
Nephron Pharmaceuticals’…
Nephron Pharmaceuticals' manufacturing facility in West Columbia, South Carolina, is still running afoul of the FDA. In its most recent Form 483 report, the agency has cited several problems that were evident in an August
Johnson & Johnson is taking…
Johnson & Johnson is taking flight with the New York Jets, joining the NFL team’s roster in a multiyear agreement as its official medical innovation sponsor.
CDx innovation is reshaping…
CDx innovation is reshaping precision oncology—discover how decentralized testing is bringing diagnostics closer to patients.
Merck KGaA plans to discontinue…
Merck KGaA plans to discontinue operations at its production plant in Arklow, Ireland, “by the end of 2028,” a company spokesperson confirmed to Fierce Pharma. The decision follows a strategic review of the products made
Moderna is backing the American…
Moderna is backing the American Lung Association’s call for people with lung diseases to get vaccinated for the upcoming respiratory virus season.
Novartis has filed suit against…
Novartis has filed suit against AstraZeneca’s rare disease unit, claiming that certain marketing materials for Alexion’s Ultomiris create an inaccurate impression of Novartis’ rival drug Fabhalta.
With plans to pay $2.1 billion to…
With plans to pay $2.1 billion to acquire its Dublin, Ireland, neighbor Avadel Pharmaceuticals, Alkermes is hoping to gain an immediate growth driver in narcolepsy drug Lumryz. But perhaps more importantly, the deal lays the
Novavax will remain headquartered…
Novavax will remain headquartered at another location nearby in Maryland as AstraZeneca takes over its former corporate headquarters in Gaithersburg.
The White House is preparing a…
The White House is preparing a probe to explore whether any U.S. trade partners aren’t paying enough for medicines, the Financial Times reported Wednesday. Unlike the administration’s previous investigation into the national security implications of
How Testosterone Is Giving Middle-Aged Women the Best Sex of Their Lives
There is no F.D.A.-approved testosterone product for women. Insurance won’t cover it. Many doctors won’t prescribe it. It’s become a cultural phenomenon.
The FDA’s recent barrage of…
The FDA’s recent barrage of letters calling out alleged violations of federal pharma marketing rules poses a challenge to drugmakers. Ad agency Real Chemistry is applying AI to the task.
With the settlement, Celltrion can…
With the settlement, Celltrion can launch its recently approved Eylea biosimilar Eydenzelt on Dec. 31, 2026, in the same indications that Eylea treats.
Healthcare and pharma companies…
Healthcare and pharma companies sometimes engage with Hispanic audiences enthusiastically—but also often neglect the growing demographic.
Axial Therapeutics has stepped…
Axial Therapeutics has stepped back into the spotlight, emerging after almost two years of silence with a new name, focus and financing.
Novo said Tuesday that it will…
Novo said Tuesday that it will host an extraordinary general meeting on Nov. 14 to elect new members to its board following an impasse in leadership discussions involving the Danish drugmaker’s chief shareholder, the Novo
The company publicly responded to…
The company publicly responded to a Citizen Petition that urges the FDA to add warnings about the use of the over-the-counter pain med during pregnancy.
After clearing Novo Nordisk’s…
After clearing Novo Nordisk’s semaglutide treatments Ozempic and Wegovy to reduce the risk of major adverse cardiovascular events (MACE), the FDA has followed suit with a MACE expansion for its semaglutide pill Rybelsus.
Private equity firm Curewell…
Private equity firm Curewell Capital is aiming to close the gap in U.S. API production with a majority investment in specialty CDMO Wilmington PharmaTech.